SG11201811745UA - T cell compositions for immunotherapy - Google Patents

T cell compositions for immunotherapy

Info

Publication number
SG11201811745UA
SG11201811745UA SG11201811745UA SG11201811745UA SG11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA SG 11201811745U A SG11201811745U A SG 11201811745UA
Authority
SG
Singapore
Prior art keywords
international
june
pct
immunotherapy
cell compositions
Prior art date
Application number
SG11201811745UA
Inventor
Alfred Slanetz
Terry Nakagawa
Marissa Herrman
Original Assignee
Geneius Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneius Biotechnology Inc filed Critical Geneius Biotechnology Inc
Publication of SG11201811745UA publication Critical patent/SG11201811745UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111110111111111011111111 01111101011H011111110011111011101111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/005712 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: (74) Agent: SOMERVILLE, Deborah, A. et al.; Fox Roth- C12N 5/078 (2010.01) CO7K 14/54 (2006.01) schild LLP, Princeton Pike Corporate Center, 997 Lenox C12N 5/0783 (2010.01) CO7K 14/55 (2006.01) Drive, Bldg. 3, Lawrenceville, NJ 08648-2311 (US). C12N 5/0786 (2010.01) A61K 35/17 (2015.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/039846 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 28 June 2017 (28.06.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (25) Filing Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, WV, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (30) Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/355,533 28 June 2016 (28.06.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/355,506 28 June 2016 (28.06.2016) US (84) Designated States (unless otherwise indicated, for every 62/355,458 28 June 2016 (28.06.2016) US kind of regional protection available): ARIPO (BW, GH, (71) Applicant: GENEIUS BIOTECHNOLOGY, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, [US/US]; 12 Michigan Drive, Natick, MA 01760 (US). UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventors: SLANETZ, Alfred, E.; 14 Nichols Road, Co- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, hasset, MA 02025 (US). NAKAGAWA, Terry, Y.; 3359 — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 5M, = Church Street, Evanston, IL 60203 (US). HERRMAN, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Marissa, A.; 1118 Saratoga Street, Apt. 2, Boston, MA KM, ML, MR, NE, 5N, TD, TG). 02128 (US). = (54) Title: T CELL COMPOSITIONS FOR IMMUNOTHERAPY = = = 10 5 cD 104 Pentamer+ 1.10 10 6 105 crs CD107a+ Gamma+ 2 22 -- :\"V 107a+ 0.46 10 6 10 5 03 TNFa 0 25 TNFa IL-2 0.059 E = Antigen 2 6 - 104 '' 104 = C D 103 _ ci_ — 0 = - 103 E (-) 10 0 3 -10 IFNg+ 1.82 1 — 0 .104 IL-2 0.14 0 10 2 10 3 10 4 10 5 = = Comp-BL1-H :: CD197-Alexa = Fluor 48 — 109-Control = CD8+ _ 127395 10 3 0 10 3 IFNy C5 109 fcs 10 4 10 5 -10 3 0 10 3 10 4 10 5 IL-2 C5 109 fcs 10 6 1111111111.11•1 10 6 = 1 0 Pentamer+ 10 5 CD10 7 a+ 62 CI Gamra+ 1 07 a+ 10 5 INF - NFa+ IL -2+ 21.1 E 104 +Antigen 1° m 4 1 -- 10 cz, v3 4 u- 1 o = 1- -. 11 a) 0 10 3 0- -10 3 c-) 0 103 -103 IFN g 10 4 0 -104 -+ IL2 3.5 ei 1-1 10 1 IN ir) Comp-BL1-H 0 --.... 00 1-1 0 (57) : The invention relates ei antigens that are useful for adoptive immunotherapy and methods for making the T cell compositions. C 10 2 10 3 10 4 10 5 :: CD197-Alexa Fluor 48 to compositions comprising -10 3 0 10 3 10 10 5 IFN 7 a heterogeneous population FIG. 6C -10 3 0 10 10 4 105 IL-2 of T cells with reactivity to selected [Continued on next page] WO 2018/005712 Al D ill Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
SG11201811745UA 2016-06-28 2017-06-28 T cell compositions for immunotherapy SG11201811745UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662355458P 2016-06-28 2016-06-28
US201662355506P 2016-06-28 2016-06-28
US201662355533P 2016-06-28 2016-06-28
PCT/US2017/039846 WO2018005712A1 (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Publications (1)

Publication Number Publication Date
SG11201811745UA true SG11201811745UA (en) 2019-01-30

Family

ID=60787739

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811745UA SG11201811745UA (en) 2016-06-28 2017-06-28 T cell compositions for immunotherapy

Country Status (11)

Country Link
US (2) US20200237819A1 (en)
EP (1) EP3487990A4 (en)
JP (3) JP7034955B2 (en)
KR (1) KR20190037243A (en)
CN (1) CN109715788A (en)
AU (2) AU2017290119A1 (en)
CA (1) CA3068387A1 (en)
IL (1) IL263896A (en)
MX (1) MX2019000180A (en)
SG (1) SG11201811745UA (en)
WO (1) WO2018005712A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3591047T3 (en) 2012-02-09 2022-12-05 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
KR101413519B1 (en) 2013-05-15 2014-07-02 전태화 The cutting and bending instrument for a lead wire
CN107429229A (en) * 2015-03-20 2017-12-01 儿童国家医疗中心 Virus or other T cells with antigenic specificity are generated from T cells colony
MX2019004707A (en) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc RE-STIMULATION OF CRYOCONSERVED INFILTRATING TUMOR LYMPHOCYTES.
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
MA46916A (en) 2016-11-17 2019-09-25 Iovance Biotherapeutics Inc RESTTUMORINFILTRIERENDE LYMPHOZYTEN UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG DAVON
JP2020503351A (en) 2017-01-06 2020-01-30 アイオバンス バイオセラピューティクス，インコーポレイテッド Proliferation of tumor infiltrating lymphocytes by potassium channel agonist and its therapeutic use
EP3572502B1 (en) 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (en) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc Operations for the production of tumor-infiltrating lymphocytes and their use in immunotherapy
US11793867B2 (en) * 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
WO2019136456A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
JP7198602B2 (en) * 2018-07-11 2023-01-04 カワサキモータース株式会社 motorcycle
JPWO2020027094A1 (en) * 2018-07-31 2021-09-16 サイアス株式会社 A method for producing a regenerated T cell population via iPS cells
WO2020025706A1 (en) * 2018-07-31 2020-02-06 Polybiocept Gmbh Production and selection of tumor uber reactive immune cells (turics)
JP2021533759A (en) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド Methods for preparing and cryopreserving cancer antigen-specific CD8 + T cells
WO2020032780A1 (en) * 2018-08-10 2020-02-13 주식회사 유틸렉스 Cancer antigen-specific cytotoxic t cells
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
US20220064597A1 (en) * 2018-12-18 2022-03-03 Beth Israel Deaconess Medical Center, Inc. Generation of organoid-primed T (opT) cells with memory phenotype
US20220064598A1 (en) * 2019-01-07 2022-03-03 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
CA3129929A1 (en) * 2019-02-14 2020-08-20 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
WO2020243729A1 (en) * 2019-05-31 2020-12-03 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
JP7337373B2 (en) * 2019-07-29 2023-09-04 サイアス株式会社 Method for producing antigen-specific T cells
WO2021041399A1 (en) * 2019-08-29 2021-03-04 Board Of Regents, The University Of Texas System Cell cryopreservation medium
JP2023504042A (en) * 2019-11-27 2023-02-01 ミスト セラピューティクス リミテッド ライアビリティ カンパニー Methods of generating tumor-reactive T-cell compositions using modulators
CA3200061A1 (en) * 2020-11-25 2022-06-02 Alfred E. Slanetz Antigen specific t cells and methods of making and using same
CN113512529B (en) * 2021-07-21 2022-11-25 上海赛傲生物技术有限公司 Preparation method of specific antiviral adoptive immune cell AB
CN113481157B (en) * 2021-07-21 2023-03-17 上海赛傲生物技术有限公司 Optimized preparation method of specific antiviral adoptive immune cells
CN113564116B (en) * 2021-07-21 2023-08-01 北京赛傲生物技术有限公司 Preparation method of specific antiviral adoptive immune cell CE
WO2023039410A1 (en) * 2021-09-08 2023-03-16 KSQ Therapeutics, Inc. Lymphocyte potency assay
EP4412628A1 (en) * 2021-10-08 2024-08-14 Baylor College of Medicine Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy
JP2023064787A (en) * 2021-10-27 2023-05-12 国立大学法人京都大学 Method for evaluating the quality of T cells and reagents used in the method
WO2023178140A2 (en) * 2022-03-18 2023-09-21 St. Jude Children's Research Hospital, Inc. Method for preparing t cells for adoptive t cell therapy
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576428B1 (en) * 1998-05-11 2003-06-10 Miltenyi Biotech Gmbh Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof
ES2545736T3 (en) * 2002-08-08 2015-09-15 Baylor College Of Medicine Isolation and identification of T cells
ES2532896T5 (en) * 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Innovative and potent MHC class II peptides derived from survivin and neurocan
RU2012111349A (en) * 2009-08-24 2013-10-27 Байлор Колледж Оф Медсин CTL LINE GENERATION WITH SPECIFICITY AGAINST MANY TUMOR ANTIGENS OR MANY VIRUSES
WO2011146473A1 (en) * 2010-05-17 2011-11-24 Duke University Methods of treatment using ex vivo expansion of cord blood t cells
US20140099341A1 (en) * 2011-05-26 2014-04-10 Alfred E. Slanetz Modulated Immunodominance Therapy
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
ES2808914T3 (en) * 2014-09-04 2021-03-02 Stemcell Tech Inc Soluble antibody complexes for the activation and expansion of T lymphocytes or NK cells

Also Published As

Publication number Publication date
AU2017290119A1 (en) 2019-01-24
IL263896A (en) 2019-01-31
WO2018005712A1 (en) 2018-01-04
EP3487990A4 (en) 2020-07-29
AU2023254998A1 (en) 2023-11-16
JP2024103547A (en) 2024-08-01
JP2022066355A (en) 2022-04-28
KR20190037243A (en) 2019-04-05
US20200237819A1 (en) 2020-07-30
CN109715788A (en) 2019-05-03
MX2019000180A (en) 2019-11-05
EP3487990A1 (en) 2019-05-29
CA3068387A1 (en) 2018-01-04
US20230145991A1 (en) 2023-05-11
JP2019519246A (en) 2019-07-11
JP7034955B2 (en) 2022-03-14

Similar Documents

Publication Publication Date Title
SG11201811745UA (en) T cell compositions for immunotherapy
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201806758VA (en) Vcn enhancer compositions and methods of using the same
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201808797XA (en) T cell receptors
SG11201909652WA (en) Neoantigen identification, manufacture, and use
SG11201908337VA (en) Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201808783XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201907857RA (en) Edible and biodegradable utensils
SG11201810591VA (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
SG11201408787PA (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11202000149VA (en) Methods and apparatus for srs antenna switching in carrier aggregation
SG11201804563SA (en) Digital microfluidic system for single-cell isolation and characterization of analytes
SG11201907508WA (en) Single slot short pucch with support for intra slot frequency hopping
SG11201807369UA (en) System and method for beam adjustment request
SG11201908675PA (en) Computer-implemented system and method for performing transaction mixing on a blockchain
SG11201906487TA (en) Service data processing method and device, and service processing method and device
SG11201807367RA (en) Indicating start and stop symbols of pdsch and pusch through pdcch
SG11201901640RA (en) Method and apparatus for reception of transmit power related information